Prolia (Denosumab) FDA Approval History

How Denosumab Works: The RANKL Mechanism

Denosumab is a fully human IgG2 monoclonal antibody that binds receptor activator of nuclear factor kappa-B ligand (RANKL) with high affinity and specificity. By blocking RANKL from activating its receptor RANK on osteoclast precursors, denosumab prevents osteoclast formation, function, and survival. The result is a rapid and sustained reduction in bone resorption.

Why RANKL Was a Therapeutic Target

Before denosumab, bisphosphonates dominated antiresorptive therapy. But bisphosphonates incorporate into the bone matrix and persist for years. Denosumab offered something different: a reversible mechanism. Because it circulates as a protein rather than binding to hydroxyapatite, its pharmacologic effects wear off within approximately 6 months of the last dose 1. That reversibility later proved to be both a clinical advantage and a safety concern.

From Bench to BLA

Amgen filed a Biologics License Application (BLA) in early 2009 for what would become Prolia. The FDA's Reproductive Health Drugs Advisory Committee reviewed the application in August 2009, voting 12 to 8 in favor of approval for postmenopausal osteoporosis. The narrow margin reflected concerns about long-term infection risk and potential effects on the immune system, since RANKL signaling plays a role in immune cell development 2.

The FREEDOM Trial: Foundation of FDA Approval

The Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial was the primary basis for Prolia's approval. Published in the New England Journal of Medicine in August 2009, this phase 3 study enrolled 7,868 postmenopausal women aged 60 to 90 with T-scores between -2.5 and -4.0 at the lumbar spine or total hip 1.

Primary Efficacy Results

Over 36 months, denosumab 60 mg every 6 months reduced the risk of new radiographic vertebral fractures by 68% compared to placebo (2.3% vs 7.2%, P<0.001). Hip fracture risk fell by 40% (0.7% vs 1.2%, P=0.04), and nonvertebral fracture risk declined by 20% (6.5% vs 8.0%, P=0.01) 1.

Safety Profile in FREEDOM

Serious adverse event rates were balanced between groups at approximately 25.8% for denosumab versus 25.1% for placebo. The trial noted numerically higher rates of eczema (3.0% vs 1.7%) and cellulitis (0.3% vs <0.1%) in the denosumab arm. No cases of osteonecrosis of the jaw (ONJ) or atypical femoral fractures were observed during the initial 3-year period. Serious infections requiring hospitalization occurred in 4.1% of denosumab patients versus 3.4% of placebo patients, a difference that did not reach statistical significance 1.

The FREEDOM Extension study followed participants for up to 10 years, providing the longest continuous exposure dataset for any antiresorptive. Bone mineral density continued to increase through year 10, and fracture rates remained low. Atypical femoral fractures were reported in 2 patients during the extension 3.

FDA Approval Timeline: A Chronological Record

Denosumab's regulatory history spans more than 15 years, with distinct approvals under two separate brand names for different clinical contexts.

Prolia Approvals (60 mg Every 6 Months)

June 1, 2010: The FDA approved Prolia for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or failure of or intolerance to other osteoporosis therapy. The approval carried a Risk Evaluation and Mitigation Strategy (REMS) requiring a Medication Guide 4.

September 2011: Label expansion to include treatment of bone loss in men receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer and women receiving aromatase inhibitor (AI) therapy for breast cancer 4.

September 2012: Approval extended to treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids at a dose of 7.5 mg or more of prednisone daily and expected to remain on glucocorticoids for at least 6 months. This made Prolia the first biologic approved for glucocorticoid-induced osteoporosis 4.

May 2018: The FDA added a new indication for treatment to increase bone mass in men with osteoporosis at high risk for fracture 4.

Xgeva Approvals (120 mg Every 4 Weeks)

November 18, 2010: Xgeva received approval for prevention of skeletal-related events in patients with bone metastases from solid tumors, based on three phase 3 trials comparing denosumab 120 mg monthly to zoledronic acid 4 mg monthly 5.

June 2013: Label expansion for treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection would result in severe morbidity 5.

January 2018: Xgeva gained approval for prevention of skeletal-related events in patients with multiple myeloma, after the initial 2010 approval had specifically excluded this population 6.

Post-Market Safety Communications

The FDA has issued several significant safety updates since initial approval. These communications reshaped clinical practice around denosumab prescribing and discontinuation.

2012: ONJ and Atypical Femoral Fractures

The FDA updated the Prolia label to include warnings about osteonecrosis of the jaw and atypical subtrochanteric and diaphyseal femoral fractures. While no ONJ cases appeared in FREEDOM's initial 3 years, post-market reports accumulated rapidly. The Xgeva label already carried ONJ warnings from launch, given the higher dose and more frequent administration 4.

2015: Hypocalcemia Boxed Warning on Xgeva

The FDA added a boxed warning to Xgeva's labeling for severe symptomatic hypocalcemia, including fatal cases. Patients with renal impairment (creatinine clearance <30 mL/min) or receiving dialysis were at highest risk. The warning mandated calcium and vitamin D supplementation, calcium monitoring, and correction of pre-existing hypocalcemia before starting Xgeva 5.

2017: Rebound Vertebral Fractures After Discontinuation

In September 2017, the FDA issued a Drug Safety Communication warning about the risk of multiple vertebral fractures after stopping Prolia. Post-market case reports and the FREEDOM Extension data showed that bone turnover markers rebound above baseline within 6 to 12 months of the last dose, and bone mineral density returns to pre-treatment levels within 12 to 18 months 7.

The clinical consequence: patients who discontinued denosumab without transitioning to an alternative antiresorptive experienced vertebral fracture rates of 7.1% versus 2.0% in those who transitioned to a bisphosphonate, according to a retrospective analysis of 1,001 patients published in the Journal of Bone and Mineral Research 7. The FDA recommended that healthcare providers consider transitioning patients to another antiresorptive if denosumab is discontinued.

2022: Updated REMS and Medication Guide

The FDA revised the Prolia REMS to incorporate stronger language about the discontinuation fracture risk. The updated Medication Guide explicitly instructs patients not to stop Prolia without talking to their healthcare provider and warns that stopping Prolia may cause rapid bone loss and increased fracture risk 4.

What the Current Prolia Label Says

The Prolia prescribing information, as revised through 2024, contains the following key sections.

Contraindications

Prolia is contraindicated in patients with hypocalcemia and in pregnant women (Pregnancy Category X). RANKL inhibition in animal studies caused fetal harm, including absent lymph nodes and abnormal bone growth 4.

Warnings and Precautions

The label lists seven discrete warnings: hypocalcemia, osteonecrosis of the jaw, atypical subtrochanteric and diaphyseal femoral fractures, multiple vertebral fractures following discontinuation, serious infections (including skin infections leading to hospitalization), dermatologic reactions (dermatitis, eczema, rashes), and musculoskeletal pain. The discontinuation warning carries the most detailed clinical guidance, spanning more than a full page of prescribing information.

Dosing and Administration

For all Prolia indications, the dose is 60 mg administered as a single subcutaneous injection in the upper arm, upper thigh, or abdomen once every 6 months. Patients must receive calcium 1,000 mg daily and at least 400 IU vitamin D daily. No dose adjustment is required for renal impairment, though patients with severe renal impairment (creatinine clearance <30 mL/min) are at greater risk of hypocalcemia 4.

International Regulatory Context

Denosumab's regulatory footprint extends well beyond the United States.

European Medicines Agency (EMA)

The EMA approved Prolia in May 2010, slightly ahead of the FDA, for treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, and for treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. The European Committee for Medicinal Products for Human Use (CHMP) noted that the benefit-risk balance was favorable but required a 10-year post-authorization safety study 8.

Global Availability

As of 2025, denosumab holds marketing authorization in more than 90 countries. Japan approved Prolia in 2012, and Health Canada approved it in 2010. Each regulatory authority has implemented slightly different post-market surveillance requirements, but the core label warnings about discontinuation fracture risk and ONJ are consistent across jurisdictions.

Biosimilar Development and Patent Field

Amgen's composition-of-matter patents for denosumab began expiring in 2025, opening the door to biosimilar competition.

Active Biosimilar Programs

Several manufacturers have advanced denosumab biosimilars through clinical development. Samsung Bioepis, Sandoz, and Fresenius Kabi all announced phase 3 biosimilar studies between 2021 and 2023. The FDA accepted the first biosimilar application for review in 2024 9.

Clinical and Economic Implications

Biosimilar introduction could substantially reduce costs. Prolia's wholesale acquisition cost in the U.S. Exceeds $1,800 per injection as of 2025, and the drug generated approximately $4.2 billion in global revenue for Amgen in 2024. Biosimilar pricing typically runs 15% to 35% below the reference product at launch, based on patterns observed with other monoclonal antibody biosimilars in the osteoporosis and oncology spaces 9.

FDA Sentinel and Post-Market Surveillance Data

The FDA Sentinel System, a distributed data network that monitors the safety of regulated medical products, has been used to evaluate denosumab outcomes in real-world populations.

Key Sentinel Findings

A 2020 Sentinel analysis examining more than 150,000 Prolia users confirmed the discontinuation fracture signal observed in clinical trials. The analysis found that patients who missed a scheduled dose by more than 8 weeks had a 2.7-fold increase in vertebral fracture risk compared to those who remained on schedule 10.

Ongoing Monitoring

The FDA continues to evaluate denosumab through multiple surveillance mechanisms, including the FDA Adverse Event Reporting System (FAERS), the Sentinel Initiative, and mandated post-marketing studies by Amgen. Active areas of monitoring include long-term ONJ incidence beyond 10 years of exposure, immunogenicity (antibody formation rates have remained below 1% in all studies to date), and cardiovascular safety signals, which have not materialized in any dataset 10.

Clinicians prescribing denosumab should document a discontinuation plan at the time of initiation, with bisphosphonate transition as the default exit strategy if therapy is stopped.